OAM
LPCN icon

Oxford Asset Management’s Lipocine LPCN Stock Holding History

Oxford Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-780
Closed -$5K – 807
2019
Q4 		$5K Buy
+780
New +$20K ﹤0.01% 1707
2016
Q2 		– Sell
-2,246
Closed -$388K – 844
2016
Q1 		$388K Sell
2,246
-962
-30% -$164K 0.01% 645
2015
Q4 		$699K Buy
+3,208
New +$673K 0.02% 609

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FPCG
Fort Pitt Capital Group Pittsburgh, Pennsylvania $3.55B AUM 34.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Asset Management's LPCN Position: Q1 2020 in Review

Oxford Asset Management sold out of Lipocine (LPCN) in Q1 2020, closing a stake of 780 shares — an estimated $5K sold.

Oxford Asset Management first reported a position in LPCN in Q4 2015 and held it in 3 quarters. The position peaked at $699K in Q4 2015. 28 funds tracked by Wall St. Rank hold LPCN as of Q1 2020.

  • Oxford Asset Management reported no remaining Lipocine position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 780 Lipocine shares in Q1 2020, an estimated $5K.
  • Oxford Asset Management first reported a position in Lipocine in Q4 2015 and held it in 3 quarters.
  • Oxford Asset Management's Lipocine position peaked at $699K in Q4 2015.
  • 28 funds tracked by Wall St. Rank held Lipocine as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.